Philips announces WE-TRUST multicenter clinical trial to assess impact of ‘Direct to Angio Suite’ workflow on stroke pati...
27 Noviembre 2019 - 09:00AM
Philips announces WE-TRUST multicenter clinical trial to assess
impact of ‘Direct to Angio Suite’ workflow on stroke patient
outcomes
November 27, 2019
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced a major clinical trial to assess the impact of a ‘Direct
to Angio Suite’ workflow on stroke patient outcomes. The study will
assess whether with Philips’ advanced image-guided therapy platform
it is possible to diagnose, plan and treat stroke patients in the
interventional suite without requiring an initial CT or MRI exam.
The multicenter, prospective, randomized, controlled, open-label,
blinded-endpoint trial will be run across eight sites and over 460
patients globally. It will begin in the first half of next year and
is expected to be completed in 2022.
Outcomes for stroke patients are closely tied to how quickly
they receive treatment: every 30 minutes’ delay before treatment
reduces the chance of a good outcome by 14% [1], and every hour of
delay ages the brain by 3.6 years compared to a normally aging
brain [2].
Currently, when a possible stroke patient arrives at the
Emergency Department, they typically first undergo a CT or MRI exam
and, in the case of an ischemic stroke, are then treated in an
interventional suite. Several studies have indicated that a Direct
to Angio Suite workflow can reduce the time to treatment and
improve patient outcomes. Philips is developing new technology to
further improve the CT-like images of the brain created with the
X-ray system in the suite. The WE-TRUST (Workflow optimization to
rEduce Time to endovascular ReperfUsion in Stroke Treatment) trial
will provide the most comprehensive assessment to-date of the
impact of this technology and workflow innovation on time to
treatment and patients’ neurological outcomes.
“Significant advances in technology mean that we are now able to
identify, plan and treat ischemic stroke patients in the
angiography suite, without the need for a separate CT or MR scan,”
said Raul G. Nogueira, MD, Director, Neuroendovascular Service
Marcus Stroke & Neuroscience Center at Grady Memorial Hospital
in Atlanta, U.S. and principal investigator for the WE-TRUST trial.
“Now is the right moment to perform a randomized controlled trial
to objectively assess the benefits of a streamlined Direct to Angio
Suite workflow on patient outcomes.”
“With extensive clinical research demonstrating the benefit of a
treatment approach that combines thrombectomy and clot-busting
drugs, stroke patient triage and treatment has changed dramatically
in recent years,” said Ronald Tabaksblat, General Manager Image
Guided Therapy Systems at Philips. “For stroke patients, ‘time is
brain’. The WE-TRUST trial will assess the impact of a streamlined
Direct to Angio Suite workflow on patient outcomes and has the
potential to make a significant impact in this rapidly advancing
field.”
The trial will primarily be carried out on Philips Azurion, the
company’s leading platform for interventional procedures, at eight
leading stroke sites in Europe and the US. The primary endpoint of
the WE-TRUST trial is patients’ cognitive function at three months
after the procedure. More information about the Direct to Angio
Suite workflow can be found at philips.com/dtas.
Philips provides a unique portfolio of systems, smart devices,
software and services in image-guided therapy, which combine to
provide healthcare providers with sophisticated, procedure-oriented
solutions.
[1] https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.021989
[2] https://www.ncbi.nlm.nih.gov/pubmed/16339467
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916Email:
mark.groves@philips.comTwitter: mark_groves
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.comTwitter: FC_Feer
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2018
sales of EUR 18.1 billion and employs approximately 80,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips_Azurion_stroke
- Philips_Azurion_aneureysm
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024